systematic therapy
PreclinicalSmall molecule
systematic therapy is one of 39 small molecule programs targeting Gastric Cancer. It is currently in Preclinical.
2
Indications
2
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
714 competitors in Gastric Cancer
#DrugCompanyPhaseTrials
1Camptosar
EEastern Cooperative Oncology Group
Phase 3
Ellence
Merck & Co.Phase 3
Chemotherapy Drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Gemzar
Johnson & JohnsonPreclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
S1,
CChinese Academy of Medical Sciences
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Induction Phase1
GenmabPreclinical
Glutamine
SanofiPreclinical
Human Albumin
TTonghua Anrate Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Leptomeningeal Metastasis1 trial
Development of a Novel Graded Prognostic Assessment (BC-LGPA) Model for Breast Cancer Leptomeningeal Metastasis
Completed·—··NCT07386886·403 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for systematic therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPeking University Third Hospital